Sign In
Buy SRPT
$17.65
+0.120 (+0.685%)
At Close: Jun 22, 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:48pm, Monday, 08'th Jun 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy
01:01pm, Monday, 08'th Jun 2026
Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SRPT vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Monday, 08'th Jun 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Sarepta Therapeutics (SRPT) or argenex SE (ARGX). But which of these two companies is the bes
Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
11:41am, Thursday, 04'th Jun 2026
Sarepta Therapeutics, Inc. (SRPT) Shareholder/Analyst Call Transcript
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
04:30pm, Monday, 01'st Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the
My Top 3 Biotech Stocks for May 2026
11:15am, Wednesday, 20'th May 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
04:30pm, Wednesday, 13'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
11:51am, Thursday, 07'th May 2026
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
11:41pm, Wednesday, 06'th May 2026
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
07:31pm, Wednesday, 06'th May 2026
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall St
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
06:25pm, Wednesday, 06'th May 2026
Sarepta Therapeutics (SRPT) came out with quarterly earnings of $3.16 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to a loss of $3.42 per share a year ago.
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 06'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2026. "W
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
11:02am, Wednesday, 29'th Apr 2026
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
08:30am, Wednesday, 22'nd Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasd
